Angiotensin-converting enzyme (ACE) inhibitors prevent bradykinin degradation allowing for accumulation of bradykinin that can cause angioedema, and it is well known that ACE inhibitor use is associated with a higher risk of developing angioedema with tPA administration [1–6]. The gene discussed is KNG1; the disease is angioedema.